Annotation Detail

Information
Associated Genes
ERBB2
Associated Variants
ERBB2 KINASE DOMAIN MUTATION
ERBB2 KINASE DOMAIN MUTATION
Associated Disease
lung adenocarcinoma
Source Database
CIViC Evidence
Description
This was a retrospective study of patients with advanced HER2-mutant NSCLC who had undergone varied courses of treatment. All tumors were adenocarcinoma with in-frame HER2 exon 20 insertions. In patients (n=57) that had been treated with trastuzumab plus chemotherapy, an overall response rate of 75% and progression free survival of 5.1 months were observed. No standard of care currently exists for HER2-mutant NSCLC. While trastuzumab has not shown clear benefit yet in wild-type HER2 overexpressed NSCLC, the authors conclude that further prospective studies should be done with trastuzumab plus chemotherapy in advanced HER2 mutant NSCLC, and that trastuzumab plus chemotherapy should be considered in current treatment courses of this cancer type.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1043
Gene URL
https://civic.genome.wustl.edu/links/genes/20
Variant URL
https://civic.genome.wustl.edu/links/variants/413
Rating
4
Evidence Type
Predictive
Disease
Lung Adenocarcinoma
Evidence Direction
Supports
Drug
Trastuzumab
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
26598547
Drugs
Drug NameSensitivitySupported
TrastuzumabSensitivitytrue